TAK875
|
|
|
- CAS-Nr.
- 1000413-72-8
- Englisch Name:
- TAK875
- Synonyma:
- CS-54;TAK875;Fasiglifam;TAK-875,TAK875;TAK-875, >=98%;TAK875 USP/EP/BP;TAK-875(Fasiglifam);FASIGLIFAM (TAK-875);TAK-875; TAK875; TAK 875.;[(3S)-6-({2',6'-Dimethyl-4'-[3-(methylsulfonyl)propoxy]-3-bi...
- CBNumber:
- CB52534865
- Summenformel:
- C29H32O7S
- Molgewicht:
- 524.63
- MOL-Datei:
- 1000413-72-8.mol
|
TAK875 Eigenschaften
- Schmelzpunkt:
- 123-127°C
- Siedepunkt:
- 739.1±60.0 °C(Predicted)
- Dichte
- 1.252
- storage temp.
- Refrigerator
- L?slichkeit
- Acetonitrile (Slightly), DMSO (Slightly), Methanol (Slightly)
- pka
- 4.36±0.10(Predicted)
- Aggregatzustand
- Solid
- Farbe
- White to Off-White
Sicherheit
- Risiko- und Sicherheitserkl?rung
- Gefahreninformationscode (GHS)
TAK875 Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
The free fatty acid receptor 1 (FFAR1; GPR40) is highly expressed in pancreatic β-cells and activated by medium and long-chain fatty acids. There is evidence of a link between FFAR1 (GPR40) and the ability of fatty acids to amplify glucose-stimulated insulin secretion, making this signaling pathway a potential target for regulating diabetes, obesity, and other metabolic disorders. TAK-875 is a selective FFAR1 (GPR40) agonist (EC
50 = 26 nM) that does not exhibit activity on the related FFARs FFAR2 (GPR43) or FFAR3 (GPR41).
Verwenden
TAK-876 is a selective G protein-coupled receptor 40 (GPR40) agonist. TAK-876 is a novel oral medication that has been developed to improve the secretion of insulin in a glucose-dependent manner, whic
h has the potential to improve the control of blood sugar levels without the risk of hypoglycemia.
TAK875 Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
TAK875 Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.
Global( 146)Lieferanten
- TAK875
- 3-Benzofuranacetic acid, 6-[[2',6'-diMethyl-4'-[3-(Methylsulfonyl)propoxy][1,1'-biphenyl]-3-yl]Methoxy]-2,3-dihydro-, (3S)-
- (3S)-6-[[2',6'-Dimethyl-4'-[3-(methylsulfonyl)propoxy][1,1'-biphenyl]-3-yl]methoxy]-2,3-dihydro-3-benzofuranacetic acid
- TAK-875, >=98%
- TAK-875,TAK875
- [(3S)-6-({2',6'-Dimethyl-4'-[3-(methylsulfonyl)propoxy]-3-biphenylyl}methoxy)-2,3-dihydro-1-benzofuran-3-yl]acetic acid
- (S)-2-(6-((2',6'-Dimethyl-4'-(3-(methylsulfonyl)propoxy)-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydrobenzofuran-3-yl)acetic acid
- Fasiglifam
- (S)-2-(6-((2',6'-Dimethyl-4'-(3-(methylsulfonyl)propoxy)-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dih
- FASIGLIFAM (TAK-875)
- CS-54
- TAK-875(Fasiglifam)
- TAK-875; TAK875; TAK 875.
- [(3S)-6-({3-[4-(3-methanesulfonylpropoxy)-2,6-dimethylphenyl]phenyl}methoxy)-2,3-dihydro-1-benzofuran-3-yl]acetic acid
- TAK875 USP/EP/BP
- [(3S)-6-({2',6'-Dimethyl-4'-[3-(methylsulfonyl)propoxy]-3-bi...
- (S)-2-(6-((2',6'-Dimethyl-4'-(3-(methylsulfonyl)propoxy)-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydrobenzofuran-3-yl)acetic acid
- 1000413-72-8
- C29H32O7S
- Inhibitors
